Terns Pharmaceuticals Overview
Latest P/E ratio for Terns Pharmaceuticals: -51.41 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-51.41
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Terns Pharmaceuticals (TERN) currently reports a P/E ratio of -51.41. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Terns Pharmaceuticals's P/E ratio history and peer comparisons.
Terns Pharmaceuticals's P/E ratio of -51.41 is lower than the Healthcare sector average of 26.85. That is roughly 291.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Terns Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -51.41, TERN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -51.41, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Terns Pharmaceuticals, and consider following TERN for alerts when major investors trade the stock.
Terns Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -51.41 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TERN with unrelated industries.
